{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-033087","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.558685+00:00","generated_at":"2026-06-04T23:48:40.724842+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Akari Therapeutics raises ~$1.615M in private placement of ADSs for working capital","bullets":["Pricing at lower of $1.57 or 0.7× 15-day VWAP, floor $1.12 per ADS, each ADS representing 2,000 ordinary shares.","Private placement expected to close on or about March 21, 2024, subject to customary conditions.","Placement agent Paulson Investment to receive 10% cash fee and warrants exercisable at 125% of offering price for 5 years.","Company agreed to file registration statement for resale of the ADSs by March 31, 2024.","Exchange cap of 1,320,616 ADSs (19.99% of outstanding ordinary shares) unless shareholder approval obtained."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-033087","json":"https://secwatch.observer/filing/0001104659-24-033087.json","markdown":"https://secwatch.observer/filing/0001104659-24-033087.md","text":"https://secwatch.observer/filing/0001104659-24-033087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000110465924033087/0001104659-24-033087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000110465924033087/tm248477d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:48:40.724842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"735352c751b3585ee52477d91a4eff2e7ed596c5","claim":"Akari Therapeutics Plc entered into Purchase Agreement with certain existing investors valued at approximately $1,615,000 (effective 2024-03-11).","evidence_excerpt":"On March 11, 2024, Akari Therapeutics, Plc (the “ Company ”) entered into a definitive agreement (the “ Purchase Agreement ”) with certain existing investors, pursuant to which the Company agreed to sell and issue in a private placement (the “ Private Placement ”) approximately $1,615,000 of unregistered American Depository Shares (“ ADSs ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000110465924033087/0001104659-24-033087-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain existing investors"},{"label":"Value","value":"approximately $1,615,000"},{"label":"Effective","value":"2024-03-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}